Background Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of sudden cardiac death (SCD), and ...
On Wednesday, FibroBiologics, Inc. (NASDAQ: FBLG) submitted a new patent application with the U.S. Patent and Trademark Office (USPTO). The patent application covers a proprietary fibroblast-derived ...
FibroBiologics Inc. FBLG on Tuesday said it completed manufacturing of the first batch of FibroBiologics' proprietary CYWC628 ...
Helmholtz Munich researchers revealed a conserved differentiation process with clinical implications for injury repair, identifying a multipotent fibroblast progenitor in the fascia— the deepest ...
FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Advancing Fibroblast Therapy on Multiple Fronts In the past month, ...
Fibrosis is the body's way of patching up damage—a bit like fixing a pothole. When skin is cut or a muscle is injured, ...
Playing a role in a variety of biological processes, including the promotion of neuronal plasticity, embryonic development, epithelial cell migration, and tumor growth and invasion, basic fibroblast ...
Researchers develop a 3D cell culture system to test how inhibiting fibroblast activities can help treat lung cancer. To simulate the tumor microenvironment and mimic real tissues, the team ...
FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results